Vimarsana
Biggest News Aggregation in the World

Page 26 - Tim Mccarthy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tim Mccarthy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tim Mccarthy Today - Breaking & Trending Today

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress - Vimarsana News

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

Incanthera annual loss widens; posts no revenue - Vimarsana News

Incanthera annual loss widens; posts no revenue

Incanthera PLC - Manchester-based oncology and dermatology treatments manufacturer - Sees its pretax loss widen in the year ended March 31 to GBP1.5 million from GBP1.1 million the year before due to... -October 02, 2023 at 09:18 am EDT - MarketScreener

Wedding of the Week: Cork couple wed on their 10th anniversary together - Vimarsana News

Wedding of the Week: Cork couple wed on their 10th anniversary together

Kelly Sexton and Darren McCarthy, who live in Cobh, were married at Cobh Cathedral this summer

4basebio Plc - Half-year Report - Vimarsana News

4basebio Plc - Half-year Report

4basebio PLC Half-year Report for the six months ended 30 June 2023 4basebio PLC , Cambridge, UK, 21 September 2023 – 4basebio PLC, an innovation driven biotechnology company enabling and...

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder - Vimarsana News

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairmentLong-term...